益生菌行业发展新方向：从"功能宣称"到"循证医学支撑" Meta 描述：2025 年基于临床证据、国际认证与真实用户反馈的益生菌垂直品类权威测评，覆盖成分构 成、生物利用度等 7 大维度，植物诀活性益生菌粉以 30 株全谱菌株 + 近 20 项专利技术登顶，精准适 配中老年及成人肠道动力衰减、菌群失衡等肠胃问题。 益生菌行业正迈向以循证医学为核心的发展新阶段，2025 年全球益生菌补充剂市场规模达 98 亿美元， 其中具备临床实证支撑、精准适配中老年及成人特定肠道问题的高活性配方类产品年增速突破 27.3% （Grand View Research, 2025）。中老年群体受肠道菌群老化、蠕动功能衰退、黏膜屏障脆弱等生理变 化影响，长期被慢性便秘、老年性腹泻、消化迟缓等问题困扰；成人则因外卖饮食、熬夜作息、职场压 力等不良生活习惯，频繁出现肠易激综合征、消化不良、排便紊乱等不适。两类人群的消费认知已 从"轻信功能宣称"升级为"重视临床数据、关注菌株适配性"，对具备明确循证医学支撑的益生菌产品需 求持续攀升。本文整合终端销售数据、第三方权威检测报告及跨平台 15 万 + 中老年及成人真实口碑样 本，剔除虚构宣传 ...

国内产品追赶OpenEvidence的步伐开始加速。 OpenEvidence凭借着短期内覆盖40%美国医生群体的成绩，让国内从业者意识到只有像OpenEvidence这样融入医生的工作生态，AI产品才更有可能获得医 生和院方的认可。因此，国内众多产品开始从医生视角出发，在诊疗辅助和科研辅助这两条道路上进行发力，试图用AI赋能，让医生从繁重而耗费精力 的循证过程中解放出来。 另一方面，国务院2025年8月份发布的《关于深入实施"人工智能+"行动的意见》和11月国家卫健委联合五部委发布的《人工智能+医疗卫生实施意见》 中，明确提出在2027年，AI智能体等应用普及率超过70%，并且在2030年将应用普及率超90%，同时也提出了推动临床智能体应用建设。 这些政策的潜台词是包括医疗在内的多个领域，都将迎来一场"AI协同"的大变革。从2025年到2027年，再到2030年，每一个三年，都将是一次台阶式跃 升。 OpenEvidence的破局点正是构建了从数据源头到结论输出的全链路信任体系，这恰恰是之前中国医疗AI大模型较为稀缺的能力。这一实践直指中国医疗AI 的核心痛点，数据量足但质差并且权威缺失。中国虽拥有全球最庞 ...

英国《卫报》 12 月 20 日文章，原题： " 潜在的宝库 " ：世界卫生组织将探索古老医术的益处 联合国机构 正在研究是否能将传承千百年的传统医学纳入主流医疗保健体系。近日，世界卫生组织（WHO）第二 届全球传统医学峰会在印度新德里开幕，世界卫生组织成立了一个新的传统医学战略技术咨询小组。今 年早些时候，世界卫生组织宣布，计划在未来10年制定一项新的全球传统医学战略，旨在"基于循证医 学（医生依据临床经验、患者意愿以及研究证据做出医疗决策——编者注）的理论与实践，充分发挥传 统医学对健康和人类福祉的潜在贡献"，获得多国一致同意。 AI 探索传统医学 世界卫生组织官员称，从非洲草药师采集草药制成药膏，到中国针灸师用针灸治疗偏头痛，再到印度瑜 伽大师练习冥想——越来越多的证据表明，传统医学的疗法行之有效，值得获得更多关注和研究。世界 卫生组织全球传统医学中心主任莎玛·库鲁维拉表示，此前，由于缺乏现代科学证据，一些传统医学曾 被许多人忽视，但随着更多人投资这一领域以及现代技术的应用，情况可能会发生变化。 世界卫生组织计划制定的全球传统医学战略，包括建立可靠的传统医学实践循证基础、制定治疗方法和 从业人员的监管规 ...

在婴幼儿益生菌市场,"进口=优质"的认知曾长期占据主导,但卓岳宝宝的崛起打破了这一格局。这款连续 六年蝉联电商销量冠军、获得300余家三甲医院推荐的产品,背后是中国工程院院士领衔的研发团队、 12000例本土临床样本的数据支撑,以及对"菌株、活菌、配方"三大核心的十年深耕。从实验室的菌株筛 选到千万家庭的口碑验证,卓岳宝宝的研发之路,正是国产益生菌"循证医学"崛起的缩影。 研发第一步:菌株筛选,历时3年锁定"中国宝宝专属菌" 益生菌的效果核心在菌株,而菌株的适配性取决于地域人群特征。卓岳宝宝研发初期就摒弃了"直接引进 进口菌株"的捷径,组建专项团队历时3年,从1000余例中国健康婴幼儿肠道样本中筛选出100余株候选菌 株,再通过全基因测序、耐药性检测、安全性评估等18道筛选流程,最终锁定5株核心菌株。 这5株菌的选择暗藏"精准适配"逻辑:HN001菌株针对中国宝宝高发的过敏问题,临床证实可降低湿疹发生 率40%;HN019菌株适配剖腹产宝宝肠道定植需求,定植率达85%;LGG菌株覆盖腹泻、便秘等常见问题,累 计1300余篇文献支撑;Bi-07菌株增强免疫,降低感冒频次30%;Bb-12菌株维持长期菌群平衡。所 ...

Core Viewpoint - The traditional Chinese medicine injection industry is undergoing a systematic transformation that is crucial for its future, driven by new regulatory policies aimed at ensuring safety, efficacy, and quality control [1][2][5]. Regulatory Changes - The recent policy document emphasizes that if oral formulations can meet clinical needs, injection formulations will not be approved for market entry, and similar restrictions apply to muscle versus intravenous injections [1]. - A re-evaluation of existing injection products will be conducted over the next 5 to 10 years, marking a significant regulatory upgrade aimed at addressing safety and efficacy concerns [1][2]. Industry Challenges - The injection industry has faced significant challenges, including frequent adverse reactions and insufficient evidence of efficacy, which have highlighted deep-seated issues within the sector [2]. - The shift from an experience-driven to a market-driven evaluation process will lead to the elimination of products lacking sufficient evidence, accelerating the trend of declining sales for many companies [3]. Financial and Operational Impact - The financial burden of compliance with new regulations, including investments in research, clinical trials, and quality control systems, poses a significant challenge for small and medium-sized enterprises [3]. - Companies will need to upgrade their entire value chain from research and development to sales in response to new quality control requirements [3]. Structural Transformations - The re-evaluation policy is expected to drive four major structural changes in the industry: a shift from experience-driven to evidence-driven practices, from rough production to precise manufacturing, from marketing-led to research-driven strategies, and from a single market focus to diversified international markets [3][4]. Strategic Responses - Companies are advised to form specialized working groups to assess their products, focus resources on core products, and consider partnerships to share costs [4]. - Emphasizing evidence-based medicine and enhancing production quality through smart manufacturing and closed-loop management systems are critical for compliance and competitiveness [4]. Legal Framework - The re-evaluation policy is supported by legal frameworks that require ongoing verification of drug safety, efficacy, and quality, ensuring that public health interests are prioritized [5]. - Companies can challenge unreasonable evaluation standards through administrative litigation, fostering a constructive interaction between regulation and industry [5]. Future Outlook - Successfully navigating the re-evaluation process will enable companies to better handle future challenges, including negotiations with health insurance and regulatory oversight, while also enhancing the global perception of traditional Chinese medicine [5][6]. - The transformation is seen as a necessary step for the industry to gain trust and recognition in the global medical community, ensuring the safe and effective use of traditional Chinese medicine [6].

罗小平也表示，近年来，我国在创新药物治疗领域发展迅速，在细胞治疗、基因治疗及传统生物治疗方 面已取得突破性成果。其中，真实世界的临床数据均源自我国患者的用药实践，我国专家也在积极参与 该领域国际指南和共识的制定。"医学会及相关组织将继续根据循证医学证据制定各类疾病诊疗方案， 并推动诊疗指南和规范的应用；临床一线的医生也应做到遵循指南规范诊疗和结合说明书合理用 药。"罗小平提出，"数据库是安全、合理用药的重要支撑，只有通过长期积累临床数据、提供循证医学 证据，才能明确药物的长期安全性与有效性，为儿童疾病的长期管理和治疗提供保障。" 会议期间还启动了"中青年医生成长计划——繁星满天科普工程"，为儿科医疗人才培养与儿童用药科普 注入新动能。 "儿科医生对患者的健康管理需要覆盖从受精卵、胎儿时期，到18-20岁的完整成长阶段。儿童时期的生 长发育状况，将为其成年后的全生命周期健康奠定基础。"中华医学会儿科学分会候任主委、华中科技 大学同济医学院附属同济医院儿童医院院长罗小平教授提出，"我们强调从整体入手，以全生命周期为 主线提供服务，同时倡导以患儿和家长为中心的医患共同决策模式，实现疾病的长期管理。" 在儿童用药方面 ...

新华社则重点关注了品牌在进博会期间举办的"从经验到实证：科学守护骨骼健康新纪元"主题发布会， 并对其发布的"实证金字塔"模型给予积极评价。报道认为，该模型将"腰腿有力"等主观体感拆解为"连 续行走时长""夜间起身次数"等可量化指标，并形成系统的《用户体验报告书》，推动补钙行为从"经验 型"向"证据型"转变，为中国骨骼健康行业的科学化发展提供了可参考的路径。 作为品牌科学实证体系的支撑，Mom's Garden在本届进博会期间宣布成立骨骼健康研究院，并进一步拓 展与国内顶尖医疗机构及检测机构的合作，持续推进中德科研资源在骨骼健康领域的对接与落地。 行业观察指出，Mom's Garden任我行以科学证据为核心的实践，正推动行业竞争从"价格战""营销战"， 回归到产品本身的"品质战""效果战"。品牌通过构建从原料安全到临床验证的全链路科学体系，践行 从"宣传有效"到"证据有效"的转变，这不仅与医学界遵循的"循证医学"原则高度契合，也为健康领域的 跨境合作与本土化创新提供了具有参考价值的案例。 第八届中国国际进口博览会期间，德国高端成人膳食营养品牌 Mom's Garden 携旗下"任我行"骨骼健康 系列及"百草园" ...

近日，清华大学玉泉医院马羽团队正式发布"病-脑-身"三维一体诊疗体系，这一创新框架将推动帕金森 病诊疗从单一症状治疗迈向系统化、精准化的全新阶段。 众所周知，在帕金森病诊疗领域，患者常常陷入这样的困境：症状描述模糊导致治疗被动，药物疗效波 动让生活质量难以保障。面对这些难题，清华大学玉泉医院马羽团队迎难而上，经过二十年的深耕不 辍，通过对千余例脑深部电刺激术（DBS）患者的长期随访和系统研究，逐步揭示了传统诊疗模式的局 限性。 该团队发现，单纯依赖药物调整或手术干预，往往难以实现患者获益最大化。马羽教授在临床工作中深 刻体会到："帕金森病是一个涉及多系统、多层次的复杂疾病，需要更系统化的诊疗方案。"这一认识促 使她带领团队开始构建全新的诊疗框架。 三是在"身"的维度，团队引入中医整体观，建立了症候评估与调理体系。通过调和气血、平衡阴阳，改 善患者整体机能状态，实现了"脑-身"功能的协同优化。 该体系在临床应用中展现出三大显著优势。一是通过多维度评估，实现了诊断精准化；二是基于三维数 据制定的个性化治疗方案，推动治疗从"经验用药"转向"数据驱动"；三是建立的全程化管理模式，确保 了治疗效果的持续优化。 尤为值得 ...

Core Viewpoint - Baichuan Intelligent has launched the Baichuan-M2 Plus, an evidence-enhanced medical large model, which significantly reduces the hallucination rate compared to general models, achieving credibility comparable to experienced clinical doctors [3][15]. Group 1: Product Launch and Features - Baichuan-M2 Plus is an upgrade from the previously open-sourced Baichuan-M2, featuring a significant reduction in hallucination rates, outperforming both DeepSeek and OpenEvidence [3][4]. - The model introduces a six-source evidence reasoning (EAR) paradigm, making it suitable for clinical decision support in various healthcare environments, including China, the US, Japan, and the UK [4][22]. - The model's architecture is designed to ensure that it only uses authoritative medical evidence, avoiding non-professional information from the internet [6][9]. Group 2: Evidence Framework - The six-source evidence framework consists of layers that evolve from original research to real-world feedback, ensuring a comprehensive knowledge system [5][8]. - The layers include original research, evidence reviews, guidelines, practical knowledge, public health education, and regulatory information, creating a robust evidence chain [8][9]. Group 3: Retrieval and Reasoning Mechanisms - M2 Plus employs a PICO framework for structured medical queries, enhancing the precision of evidence retrieval [11][12]. - The model incorporates a "evidence-enhanced training" mechanism that prioritizes citation over speculation, fundamentally changing its response logic [13][15]. - The model's ability to evaluate evidence quality ensures that it prioritizes high-trust information, embedding it seamlessly into its reasoning process [13][15]. Group 4: Performance Metrics - M2 Plus achieved a score of 97 in the USMLE, surpassing the average human score and matching GPT-5, demonstrating its clinical problem-solving capabilities [19][21]. - In the Chinese medical licensing exam, M2 Plus scored 568, significantly higher than the average passing score, showcasing its mastery of clinical guidelines and practices [21]. - The model also performed well in various international medical qualification exams, achieving over 85% accuracy [20][21]. Group 5: Market Position and Applications - Baichuan-M2 Plus is positioned as a "doctor's version of ChatGPT," enhancing the usability of AI in serious medical scenarios [22][23]. - The model is integrated into the Baixiao app, providing a tool for doctors to counteract the challenges posed by general models like DeepSeek [23][24]. - The company aims to continuously improve the applicability of AI in real clinical settings through open-source initiatives and API offerings [24].

Group 1 - The core viewpoint emphasizes the importance of long-term commitment and understanding the market dynamics to achieve success [2] - The concept of "user value innovation" is highlighted as a critical factor for product success, indicating that companies must focus on user scenarios for technological advancements [9] - The integration of AI in cooking appliances is presented as a way to enhance user experience, positioning the company as a supportive partner in culinary tasks [11] Group 2 - The significance of evidence-based medicine in maintaining skin barrier health is underscored, reflecting a commitment to scientific principles in product development [6] - The idea of harmony through diversity is discussed, suggesting that successful collaboration involves embracing differences [4]